Evidence map›Paper›PMID 38399336›Full record

ArticlePharmaceutics2024

Design, Synthesis, and Antitumor Evaluation of an Opioid Growth Factor Bioconjugate Targeting Pancreatic Ductal Adenocarcinoma.

Justyna Budka, Dawid Debowski, Shaoshan Mai, Magdalena Narajczyk, Stanislaw Hac, Krzysztof Rolka, Eirinaios I Vrettos, Andreas G Tzakos, Iwona Inkielewicz-Stepniak

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Justyna BudkaDepartment of Pharmaceutical Pathophysiology, Medical University of Gdansk, 80-210 Gdansk, Poland.ORCID 0000-0002-0891-1760
Dawid DebowskiDepartment of Molecular Biochemistry, University of Gdansk, 80-309 Gdansk, Poland.ORCID 0000-0002-5868-3276
Shaoshan MaiDepartment of Pharmaceutical Pathophysiology, Medical University of Gdansk, 80-210 Gdansk, Poland.ORCID 0000-0001-8165-4580
Magdalena NarajczykBioimaging Laboratory, Faculty of Biology, University of Gdansk, 80-309 Gdansk, Poland.ORCID 0000-0001-9806-8844
Stanislaw HacDepartment of General Endocrine and Transplant Surgery, Medical University of Gdansk, 80-210 Gdansk, Poland.
Krzysztof RolkaDepartment of Molecular Biochemistry, University of Gdansk, 80-309 Gdansk, Poland.ORCID 0000-0002-4537-700X
Eirinaios I VrettosDepartment of Chemistry, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0002-4801-1900
Andreas G TzakosDepartment of Chemistry, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0001-6391-0288
Iwona Inkielewicz-StepniakDepartment of Pharmaceutical Pathophysiology, Medical University of Gdansk, 80-210 Gdansk, Poland.
Gdańsk Medical University · PLUniversity of Gdańsk · PLUniversity of Ioannina · GR

Funding

Hellenic Foundation for Research and Innovation code: 991, PROTECTNational Science Center OPUS 18 2019/35/B/NZ7/04212
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) presents a formidable challenge with high lethality and limited effective drug treatments. Its heightened metastatic potential further complicates the prognosis. Owing to the significant toxicity of current chemotherapeutics, compounds like [Met

Indexed as

gemcitabine[Met5]-enkephalinopioid growth factorpancreatic cancerpancreatic cancer organoidspeptide-drug conjugatesplateletsselective cytotoxicityTCIPA

Identifiers

PMID38399336
PMCPMC10892429
OpenAlexW4391883635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.